Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
Launched by NEMA RESEARCH, INC. · Sep 25, 2006
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
To determine the safety and efficacy of Cesamet™ in the symptomatic treatment of chemotherapy-induced neuropathic pain.
This is a phase IV, multicenter, open label of Cesamet™ at 1 mg daily progressing to 2mg BID in subjects with chemotherapy-induced neuropathic pain. This study has two phases: A pretreatment phase and a treatment phase.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with chemotherapy-induced neuropathic pain.
- • Chronic daily pain present for at least 2 months.
- • On stable analgesic regimen for one month.
- • Baseline pain score greater than 40mm on a VAS.
- Exclusion Criteria:
- • Hypersensitivity to compounds in study drug or similar drugs
- • Pregnant or lactating females
- • Drug or alcohol abuse
- • Unstable medical condition
About Nema Research, Inc.
Nema Research, Inc. is a leading clinical trial sponsor dedicated to advancing medical innovation through rigorous research and development. With a focus on therapeutic areas including oncology, neurology, and rare diseases, the company is committed to conducting high-quality clinical trials that adhere to regulatory standards and ethical guidelines. Nema Research leverages a robust network of experienced investigators and cutting-edge technology to accelerate the drug development process, ensuring the delivery of safe and effective treatment options to patients in need. Through collaboration and a patient-centered approach, Nema Research aims to contribute significantly to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aventura, Florida, United States
Naples, Florida, United States
Patients applied
Trial Officials
Joseph V Pergolizzi, MD
Principal Investigator
NEMA Research, Inc.
Charlotte A Richmond, PhD
Study Director
NEMA Research, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials